Selected article for: "global pandemic and million people"
Author: Hertanto, Decsa Medika; Wiratama, Bayu Satria; Sutanto, Henry; Wungu, Citrawati Dyah Kencono
Title: Immunomodulation as a Potent COVID-19 Pharmacotherapy: Past, Present and Future
  • Cord-id: 2635es8k
  • Document date: 2021_7_20
    • ID: 2635es8k
    Snippet: In the first year of its appearance, the 2019 coronavirus disease (COVID-19) has affected more than 150 million individuals and killed 3 million people worldwide. The pandemic has also triggered numerous global initiatives to tackle the newly emerging disease, including the development of SARS-CoV-2 vaccines and the attempt to discover potential pharmacological therapies. Nonetheless, despite the success of SARS-CoV-2 vaccine development, COVID-19 therapy remains challenging. Several repurposed
    Document: In the first year of its appearance, the 2019 coronavirus disease (COVID-19) has affected more than 150 million individuals and killed 3 million people worldwide. The pandemic has also triggered numerous global initiatives to tackle the newly emerging disease, including the development of SARS-CoV-2 vaccines and the attempt to discover potential pharmacological therapies. Nonetheless, despite the success of SARS-CoV-2 vaccine development, COVID-19 therapy remains challenging. Several repurposed drugs that were documented to be useful in small clinical trials have been shown to be ineffective in larger studies. Additionally, the pathophysiology of SARS-CoV-2 infection displayed the predominance of hyperinflammation and immune dysregulation in inducing multiorgan damage. Therefore, the potential benefits of both immune modulation and suppression in COVID-19 have been extensively discussed. Here, we reviewed the roles of immunomodulation as potential COVID-19 pharmacological modalities based on the existing data and proposed several new immunologic targets to be tested in the foreseeable future.

    Search related documents:
    Co phrase search for related documents
    • abl inhibitor imatinib and acute respiratory syndrome: 1, 2, 3
    • accelerate improvement and acute respiratory distress syndrome: 1
    • accelerate improvement and acute respiratory failure: 1
    • accelerate improvement and acute respiratory syndrome: 1, 2, 3
    • accelerate improvement and long covid: 1
    • accelerate improvement and lopinavir ritonavir: 1, 2, 3, 4, 5, 6
    • action exact mechanism and acute respiratory syndrome: 1, 2, 3
    • action exact mechanism unclear and acute respiratory syndrome: 1
    • acute respiratory distress syndrome and long covid: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory distress syndrome and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory distress syndrome and low lactate: 1, 2, 3
    • acute respiratory distress syndrome and low lactate dehydrogenase: 1, 2
    • acute respiratory distress syndrome and low mortality: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory distress syndrome patient and long covid: 1, 2, 3, 4
    • acute respiratory distress syndrome patient and lopinavir ritonavir: 1
    • acute respiratory distress syndrome patient and low mortality: 1
    • acute respiratory failure and long covid: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • acute respiratory failure and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • acute respiratory failure and low mortality: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17